MX2020004688A - Nuevos analogos como moduladores del receptor de androgenos y del receptor de glucocorticoides. - Google Patents
Nuevos analogos como moduladores del receptor de androgenos y del receptor de glucocorticoides.Info
- Publication number
- MX2020004688A MX2020004688A MX2020004688A MX2020004688A MX2020004688A MX 2020004688 A MX2020004688 A MX 2020004688A MX 2020004688 A MX2020004688 A MX 2020004688A MX 2020004688 A MX2020004688 A MX 2020004688A MX 2020004688 A MX2020004688 A MX 2020004688A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- androgen receptor
- glucocorticoid receptor
- modulators
- glucocorticoid
- Prior art date
Links
- 102100032187 Androgen receptor Human genes 0.000 title abstract 3
- 108010080146 androgen receptors Proteins 0.000 title abstract 3
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 abstract 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a derivados de dihidropiridina novedosos de fórmula (I): Ver fórmula. como moduladores de receptores nucleares seleccionados del receptor de andrógenos y del receptor de glucocorticoides, a procedimientos para su preparación, a composiciones farmacéuticas que comprenden dichos compuestos y al uso de los mismos para la fabricación de un medicamento para el tratamiento de enfermedades o estados patológicos que pueden mejorar mediante la modulación del receptor de andrógenos y/o del receptor de glucocorticoides, seleccionados de cáncer, cánceres metastatizantes, hiperplasia prostática benigna, síndrome de ovario poliquístico (SOPO), caída del cabello, hirsutismo, acné, hipogonadismo, enfermedades de emaciación muscular, caquexia, síndrome de Cushing, aumento de peso inducido por fármacos antipsicóticos, obesidad, trastorno de estrés postraumático y alcoholismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382741.1A EP3480201A1 (en) | 2017-11-06 | 2017-11-06 | New analogs as androgen receptor and glucocorticoid receptor modulators |
| PCT/EP2018/080367 WO2019086720A1 (en) | 2017-11-06 | 2018-11-06 | New analogs as androgen receptor and glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004688A true MX2020004688A (es) | 2020-08-20 |
Family
ID=60327253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004688A MX2020004688A (es) | 2017-11-06 | 2018-11-06 | Nuevos analogos como moduladores del receptor de androgenos y del receptor de glucocorticoides. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11453660B2 (es) |
| EP (2) | EP3480201A1 (es) |
| JP (1) | JP7239246B2 (es) |
| KR (1) | KR102762303B1 (es) |
| CN (1) | CN111491935B (es) |
| AU (1) | AU2018361566B2 (es) |
| CA (1) | CA3079804A1 (es) |
| DK (1) | DK3707143T3 (es) |
| EA (1) | EA202091148A1 (es) |
| ES (1) | ES2941263T3 (es) |
| FI (1) | FI3707143T3 (es) |
| HR (1) | HRP20230270T1 (es) |
| HU (1) | HUE061436T2 (es) |
| LT (1) | LT3707143T (es) |
| MX (1) | MX2020004688A (es) |
| PL (1) | PL3707143T3 (es) |
| PT (1) | PT3707143T (es) |
| RS (1) | RS64101B9 (es) |
| SI (1) | SI3707143T1 (es) |
| WO (1) | WO2019086720A1 (es) |
| ZA (1) | ZA202002920B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102737686B1 (ko) * | 2021-09-10 | 2024-12-03 | 계명대학교 산학협력단 | Jnj38877605를 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
| CN113979883A (zh) * | 2021-12-08 | 2022-01-28 | 新华制药（寿光）有限公司 | 一种乙酰乙酰苯胺高效精制工艺及其设备 |
| JP2025507378A (ja) | 2022-02-14 | 2025-03-18 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルスナフチリジノン化合物 |
| CN116496296A (zh) * | 2022-09-02 | 2023-07-28 | 河南师范大学 | 具有抗肿瘤功用的度鲁特韦衍生物及其制备方法 |
| WO2024229221A1 (en) * | 2023-05-03 | 2024-11-07 | Capulus Therapeutics, Llc | Androgen receptor modulators and methods for their use |
| CN117298108A (zh) * | 2023-09-07 | 2023-12-29 | 浙江师范大学 | 雄激素受体和糖皮激素受体双靶抑制剂及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659717A (en) * | 1985-08-21 | 1987-04-21 | Eli Lilly And Company | Dihydropyridines useful in the treatment of angina and stroke |
| US4902694A (en) * | 1988-08-11 | 1990-02-20 | Eli Lilly And Company | Dihydropyridine calcium channel modulators |
| DE4321030A1 (de) * | 1993-06-24 | 1995-01-05 | Bayer Ag | 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel |
| WO2005016885A2 (en) | 2003-08-14 | 2005-02-24 | Artesian Therapeutics, Inc. | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| EP1814554A1 (en) | 2004-10-25 | 2007-08-08 | Cytokinetics, Inc. | Certain compounds, compositions, and methods |
| US20090298872A1 (en) * | 2004-12-13 | 2009-12-03 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
| US20100119599A1 (en) * | 2006-12-08 | 2010-05-13 | Archer Pharmaceuticals, Inc. | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
| MY148851A (en) * | 2006-12-14 | 2013-06-14 | Bayer Ip Gmbh | Dihydropyridine derivatives as useful as protein kinase inhibitors |
| JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| TWI365185B (en) | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
| PT3111950T (pt) | 2012-02-24 | 2021-10-19 | Univ Chicago | Métodos e composições relacionadas com antagonismo recetor de glucocorticoide e cancro da próstata |
| WO2017059401A2 (en) * | 2015-10-01 | 2017-04-06 | Duke University | Androgen receptor ligands |
-
2017
- 2017-11-06 EP EP17382741.1A patent/EP3480201A1/en not_active Withdrawn
-
2018
- 2018-11-06 HU HUE18795687A patent/HUE061436T2/hu unknown
- 2018-11-06 SI SI201830883T patent/SI3707143T1/sl unknown
- 2018-11-06 LT LTEPPCT/EP2018/080367T patent/LT3707143T/lt unknown
- 2018-11-06 HR HRP20230270TT patent/HRP20230270T1/hr unknown
- 2018-11-06 PL PL18795687.5T patent/PL3707143T3/pl unknown
- 2018-11-06 RS RS20230220A patent/RS64101B9/sr unknown
- 2018-11-06 KR KR1020207015024A patent/KR102762303B1/ko active Active
- 2018-11-06 EA EA202091148A patent/EA202091148A1/ru unknown
- 2018-11-06 EP EP18795687.5A patent/EP3707143B9/en active Active
- 2018-11-06 WO PCT/EP2018/080367 patent/WO2019086720A1/en not_active Ceased
- 2018-11-06 MX MX2020004688A patent/MX2020004688A/es unknown
- 2018-11-06 JP JP2020524345A patent/JP7239246B2/ja active Active
- 2018-11-06 US US16/761,921 patent/US11453660B2/en active Active
- 2018-11-06 FI FIEP18795687.5T patent/FI3707143T3/fi active
- 2018-11-06 DK DK18795687.5T patent/DK3707143T3/da active
- 2018-11-06 CN CN201880081730.5A patent/CN111491935B/zh active Active
- 2018-11-06 ES ES18795687T patent/ES2941263T3/es active Active
- 2018-11-06 CA CA3079804A patent/CA3079804A1/en active Pending
- 2018-11-06 PT PT187956875T patent/PT3707143T/pt unknown
- 2018-11-06 AU AU2018361566A patent/AU2018361566B2/en active Active
-
2020
- 2020-05-19 ZA ZA2020/02920A patent/ZA202002920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021501760A (ja) | 2021-01-21 |
| ES2941263T3 (es) | 2023-05-19 |
| US11453660B2 (en) | 2022-09-27 |
| PL3707143T3 (pl) | 2023-06-05 |
| RS64101B9 (sr) | 2023-08-31 |
| EP3707143B9 (en) | 2023-04-12 |
| PT3707143T (pt) | 2023-04-03 |
| CA3079804A1 (en) | 2019-05-09 |
| CN111491935B (zh) | 2023-08-22 |
| BR112020008640A2 (pt) | 2020-10-20 |
| LT3707143T (lt) | 2023-03-27 |
| AU2018361566B2 (en) | 2023-11-02 |
| WO2019086720A1 (en) | 2019-05-09 |
| KR20200084871A (ko) | 2020-07-13 |
| RS64101B1 (sr) | 2023-04-28 |
| EP3707143A1 (en) | 2020-09-16 |
| EA202091148A1 (ru) | 2020-08-12 |
| DK3707143T3 (da) | 2023-03-27 |
| CN111491935A (zh) | 2020-08-04 |
| ZA202002920B (en) | 2024-09-25 |
| US20200325123A1 (en) | 2020-10-15 |
| HRP20230270T1 (hr) | 2023-04-14 |
| JP7239246B2 (ja) | 2023-03-14 |
| HUE061436T2 (hu) | 2023-06-28 |
| AU2018361566A1 (en) | 2020-05-14 |
| SI3707143T1 (sl) | 2023-05-31 |
| EP3480201A1 (en) | 2019-05-08 |
| KR102762303B1 (ko) | 2025-02-03 |
| EP3707143B1 (en) | 2022-12-28 |
| FI3707143T3 (fi) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202002920B (en) | New analogs as androgen receptor and glucocorticoid receptor modulators | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| BR112018014015A2 (pt) | derivados de tioidantoína substituídos como antagonistas do receptor de androgênio | |
| NI201000090A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
| BR112013023028A2 (pt) | composto da fórmula, composição farmacêutica e formulação farmacêutica tópica | |
| NI201000110A (es) | Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno. | |
| UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX2021013774A (es) | Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares. | |
| MX2019002845A (es) | Silanos y composiciones curables que comprenden dichos silanos. | |
| MX2019015350A (es) | Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis. | |
| CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
| CO2020007222A2 (es) | Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida | |
| MX2018007844A (es) | Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo. | |
| UY32426A (es) | Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| EA201990565A1 (ru) | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид | |
| BR112017007014A2 (pt) | derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii | |
| CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CY1122231T1 (el) | Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη | |
| CL2010000804A1 (es) | Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer. | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CL2023001021A1 (es) | Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1b |